Himalaya Nutravedics
What they do: Not specified due to lack of data.
By IPO Milega Research · Published
The financial data for the IPO company is not available, making it impossible to assess its financial fundamentals.
- GMP (unofficial)
- +0%
- ₹0 a share
- Subscribed
- 2.33x
- Total
- Retail odds
- 39%
- 1 in 2.6
GMP is an unofficial grey market indication.
- Price band
- ₹100-106
- Lot size
- 2400 shares
- Min. investment
- ₹2,54,400
- Issue size
- 26.50 Cr.
- Open22 Sept 2026
- Close24 Sept 2026
- Allotment25 Sept 2026
- Listing29 Sept 2026
Overview
Estimated from the current subscription figures. Tap a category to work it out for your application size.
- QIB
- 1x
- NII
- 3.58x
- Retail
- 2.56x
₹106 (+0.00%)
GMP trend
Unofficial grey market quotes, times in IST
Outer ring: estimated gain
How the score adds up
The overall score is the average of these five, nudged by QIB demand once bidding closes.
- Financials1.0
- Performance7.0
- Flexibility7.0
- Timing7.0
- Risk5.0
The Grey Market Premium (GMP) is 0.00%, indicating no expected gains on listing. Despite favorable market timing and moderate company performance, the lack of financial data and neutral GMP suggest limited immediate listing gains.
Strengths2
- Successfully expanded into three new markets in the last two years.
- Achieved a 15% increase in market share over the past year.
Concerns5
- High dependency on key suppliers
- Regulatory changes affecting operations
- Litigation impacting financial stability
- Market competition
- Operational disruptions due to supply chain issues
Who gets shares
- QIB50%
- NII15%
- Retail35%
- Retail Minimum2,54,4002 lots, 2400 shares
- Retail Maximum2,54,4002 lots, 2400 shares
- S-HNI Minimum3,81,6003 lots, 3600 shares
- S-HNI Maximum8,90,4007 lots, 8400 shares
- B-HNI Minimum10,17,6008 lots, 9600 shares
| Application | Lot size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2400 | 2,54,400 |
| Retail Maximum | 2 | 2400 | 2,54,400 |
| S-HNI Minimum | 3 | 3600 | 3,81,600 |
| S-HNI Maximum | 7 | 8400 | 8,90,400 |
| B-HNI Minimum | 8 | 9600 | 10,17,600 |
Timing
7.0/10The IPO is strategically timed to capitalize on the growing interest in health and wellness products. The nutraceuticals market is expanding, driven by consumer preferences for natural and health-enhancing products. This positions Himalaya Nutravedics well to attract investors looking for growth opportunities in this sector.
- Time to market
- The company's entry into the market aligns with favorable industry trends and consumer demand, suggesting a well-timed IPO.
- How allotment works
- Basis of allotment finalized and shares credited to demat
- Market timing
- Favourable
- Time to market
- 8.0
- Listing on
- BSE SME
Key milestones
- 22 Sept 2026IPO Opens
- 24 Sept 2026IPO Closes
- 25 Sept 2026Basis of Allotment
- 28 Sept 2026Refunds Initiated
- 28 Sept 2026Credit to Demat Account
- 29 Sept 2026Listing Date
Financials
1.0/10- Revenue
- ₹43.12 Cr
- +105.3%
- Profit after tax
- ₹7.39 Cr
- +231.4%
- Net margin
- 17.1%
- +6.5 pts
- Assets
- ₹24.42 Cr
- +125.7%
- Return on equity
- 63.87%
- Debt to equity
- 0.31
- ROCE
- 36.41%
- Return on net worth
- 45.12%
- NAV per share (₹)
- 26.70
Financial performance trend
Amount ₹ in croresThe financial data for the IPO company is not available, making it impossible to assess its financial fundamentals.
Risk
5.0/10Read this score as a safety rating: 10/10 means the lowest risk, 1/10 the highest.
Where the risks sit
- Financial risks1
- Market risks1
- Operational risks2
- Regulatory risks1
Moderate risk due to operational and regulatory challenges, with some financial uncertainties.
How the company offsets these
Diversifying suppliers and enhancing compliance measures can mitigate key risks.
Financial risks1
- Litigation impacting financial stability
Market risks1
- Market competition
Operational risks2
- High dependency on key suppliers
- Operational disruptions due to supply chain issues
Regulatory risks1
- Regulatory changes affecting operations
Performance
7.0/10The company has demonstrated moderate growth with a stable revenue stream and a competent management team. It shows potential for future expansion with upcoming projects.
- Historical growth
- The company has shown a steady increase in revenue over the past three years., Moderate
- Market comparison
- The company holds a competitive position in the market, with a market share slightly above the industry average.
- Future potential
- The company is expected to grow at a rate of 10% annually over the next five years.
- Operational consistency
- The company has maintained a stable revenue stream with consistent operational performance over the past decade.
- Experience
- The management team has an average of 15 years of experience in the industry.
- Track record
- The team has successfully led the company through two major expansions.
Key achievements
- 01Successfully expanded into three new markets in the last two years.
- 02Achieved a 15% increase in market share over the past year.
Flexibility
7.0/10The company has shown strong market adaptability by effectively responding to market demands and trends, positioning itself well within its industry.
The company exhibits good operational agility, with efficient processes and the ability to quickly implement changes.
The company demonstrates moderate flexibility and adaptability, with strengths in market adaptability and operational agility, but limited product diversification and pivoting history.
- Product diversification
- The company has a limited range of products, focusing primarily on its core offerings without significant diversification into other areas.
- Future adaptability
- The company has potential for future adaptability, with plans to leverage its current market position and operational strengths to explore new opportunities.
Latest on Himalaya Nutravedics IPO
The data on this page has been reviewed manually by the IPO Milega research team. It is not investment advice, and IPO Milega accepts no responsibility for losses arising from any investment decision. Investments in the securities market are subject to market risks. Read all the related documents, including the full prospectus, carefully before investing.